Artificial neural network modeling of antimycobacterial chemical space to introduce efficient descriptors employed for drug design

被引:10
作者
Sardari, Soroush [1 ]
Kohanzad, Houshmand [3 ]
Ghavami, Ghazaleh [1 ,2 ]
机构
[1] Inst Pasteur, Biotechnol Res Ctr, Dept Med Biotechnol, Drug Design & Bioinformat Unit, Tehran 13164, Iran
[2] Inst Pasteur, Eastern Mediterranean Hlth Genom & Biotechnol Net, Tehran 13164, Iran
[3] Minist Hlth & Med Educ, Tehran, Iran
关键词
Computational biology; ANN modeling; Chemical informatics; Anti-infective; Anti-tubercular agents; Antimycobacterial; Descriptors; Drug design; Drug Modeling; IN-VITRO ACTIVITY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; S-CONJUGATE AMIDASE; BIOLOGICAL EVALUATION; ANTITUBERCULAR ACTIVITY; PHOSPHONATE INHIBITORS; GLUTAMINE-SYNTHETASE; VIVO ACTIVITIES; ANTIGEN; 85C; DERIVATIVES;
D O I
10.1016/j.chemolab.2013.09.011
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Tuberculosis has become a serious condition with an estimated 2 million deaths each year in the world. According to WHO report, multi-resistant tuberculosis is responsible for approximately 460 thousand recent cases per year and for about 740 thousand patients infected by both Mycobacterium tuberculosis and HIV/AIDS. In the current study, several bioactive structure databases were analyzed using cheminformatics tools to correlate the chemical structures of different compounds with their pharmacological activities; in addition, these tools were tried to identify molecules that could be candidate for experimental assays. In this regard, for defining the effective chemical compounds against Mycobacterium, a database consisting of 400 antimycobacterial compounds has been constructed. In the next step, more than 1400 molecular descriptors were defined by DRAGON application server for each compound. Then, the resulting descriptors were clustered by kNN and k-means clustering methods to be employed for ANN modeling. Utilizing PLS and ANN modeling methods led to building a model for predicting minimum inhibitory concentration (MIC) with R-2 = 0.98 and MSE = 0.0002. Applying the mentioned cheminformatics tools, it would be possible to design and introduce new compounds with broad applications in antimycobacterial drug discovery and development. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 151 条
[1]   A new synthetic access to furo[3,2-f]chromene analogues of an antimycobacterial [J].
Alvey, Luke ;
Prado, Soizic ;
Huteau, Valerie ;
Saint-Joanis, Brigitte ;
Michel, Sylvie ;
Koch, Michel ;
Cole, Stewart T. ;
Tillequin, Francois ;
Janin, Yves L. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (17) :8264-8272
[2]   Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents [J].
Andrade, Carolina H. ;
Salum, Livia de B. ;
Castilho, Marcelo S. ;
Pasqualoto, Kerly F. M. ;
Ferreira, Elizabeth I. ;
Andricopulo, Adriano D. .
MOLECULAR DIVERSITY, 2008, 12 (01) :47-59
[3]   Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones [J].
Anquetin, Guillaume ;
Greiner, Jacques ;
Mahmoudi, Nassira ;
Santillana-Hayat, Maud ;
Gozalbes, Rafael ;
Farhati, Khemais ;
Derouin, Francis ;
Aubry, Alexandra ;
Cambau, Emmanuelle ;
Vierling, Pierre .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (12) :1478-1493
[4]   Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency [J].
Anthony R.M. ;
Schuitema A.R.J. ;
Bergval I.L. ;
Brown T.J. ;
Oskam L. ;
Klatser P.R. .
Annals of Clinical Microbiology and Antimicrobials, 4 (1)
[5]  
Ashish K., TETRAHEDRON, V9, P10239
[6]   Novel inhibitors of an emerging target in Mycobacterium tuberculosis;: Substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis [J].
Babaoglu, K ;
Page, MA ;
Jones, VC ;
McNeil, MR ;
Dong, CJ ;
Naismith, JH ;
Lee, RE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (19) :3227-3230
[7]   Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex [J].
Bemer-Melchior, P ;
Bryskier, A ;
Drugeon, HB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :571-575
[8]   Antimycobacterial compounds. New pyrrole derivatives of BM212 [J].
Biava, M ;
Porretta, GC ;
Deidda, D ;
Pompei, R ;
Tafi, A ;
Manetti, F .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (06) :1453-1458
[9]   Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward mycobacterium tuberculosis and low cytotoxicity [J].
Biava, Mariangela ;
Cesare Porretta, Giulio ;
Poce, Giovanna ;
Supino, Sibilla ;
Deidda, Delia ;
Pompei, Raffaello ;
Molicotti, Paola ;
Manetti, Fabrizio ;
Botta, Maurizio .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (16) :4946-4952
[10]   rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism [J].
Bobadilla-del-Valle, M ;
Ponce-de-Leon, A ;
Axenas-Huertero, C ;
Vargas-Alarcon, G ;
Kato-Maeda, M ;
Small, PM ;
Couary, P ;
Ruiz-Palacios, GM ;
Sifuentes-Osornio, J .
EMERGING INFECTIOUS DISEASES, 2001, 7 (06) :1010-1013